FDA Clears Pancreatic Pill

WashingtonMedian survival nearly doubled, to 13.2 months.

It is the first drug to target the mutation driving most pancreatic cancer, not just its symptoms.

RAS proteins had no pocket for small molecules to grip; daraxonrasib builds one using a chaperone protein.

Revolution Medicines has not disclosed a price, though the FDA approved it six months early.

Sources: Bloomberg Business, The Guardian